Myriad Genetics at Goldman Sachs Conference: Strategic Growth Amid Challenges

During the Goldman Sachs 46th Annual Global Healthcare Conference, Myriad Genetics (MYGN) expressed cautious optimism, aiming for high single-digit to low double-digit revenue growth driven by its hereditary cancer, molecular profiling, MRD, and prenatal testing segments. Despite challenges including EMR integration issues and UnitedHealthcare's GeneSight coverage decision, Myriad is focused on profitability, maintaining gross margins around 70%, and strategically investing in EMR integrations, MRD, and Pathomic while reducing discretionary spending. The company is leveraging partnerships, such as with Pathomic for AI integration in Prolaris, and technological advancements like the largely complete Lab of the Future, to enhance product offerings and drive future margin improvements; however, the impact of UnitedHealthcare's decision on GeneSight coverage remains a headwind.

Analysis

Myriad Genetics (MYGN) presented a cautiously optimistic outlook at the Goldman Sachs 46th Annual Global Healthcare Conference, outlining a strategy focused on achieving high single-digit to low double-digit long-term revenue growth. This growth is expected to be driven by its core segments: hereditary cancer, where it anticipates mid-to-high single-digit growth; molecular profiling, including Prolaris and comprehensive genomic profiling, targeted for high single-digit to low double-digit growth; Minimal Residual Disease (MRD), with its PRECISE MRD test for low-shedding tumors expected to drive double-digit growth post its H1 2026 launch; and prenatal testing, aiming to at least match market growth. The company is committed to maintaining strong gross margins, currently around 70%, and enhancing operational efficiency through initiatives like the nearly completed "Lab of the Future," which is projected to improve cost per test. Strategic investments are being channeled into EMR integrations (with 4,500 completed last year, though specific challenges with Epic for unaffected hereditary cancer are being actively addressed), MRD development, and the Pathomic partnership to integrate AI into Prolaris. However, Myriad faces significant headwinds, primarily from UnitedHealthcare's coverage decision on GeneSight, which has compelled an adjustment in GeneSight's growth expectations to low-to-mid-single-digits and a strategic pivot towards profitability for this product; management does not factor a reversal of UNH's decision into its forecasts. Despite this, average selling prices (ASPs) for the rest of Myriad's portfolio remain robust, and no further payer coverage losses for GeneSight have materialized, with some new, albeit smaller, coverage wins. Management also acknowledged investor concerns about the company's valuation, noting it trades below a one-time revenue multiple, and highlighted the need to more effectively communicate the clinical and economic benefits of its diagnostic tests.

Key Decisions for Investors

• Investors should closely monitor Myriad's execution on resolving EMR integration challenges, particularly with Epic, and track the clinical adoption and commercial ramp-up of its PRECISE MRD test following its anticipated H1 2026 launch, as these are critical to achieving its long-term revenue growth targets.
• Evaluate Myriad's ability to sustain its approximately 70% gross margin and realize projected cost efficiencies from the "Lab of the Future" initiative, especially while navigating strategic investments and the moderated growth outlook for GeneSight due to UnitedHealthcare's coverage decision.
• Consider the current valuation in the context of Myriad's growth pipeline in hereditary cancer, molecular profiling, and MRD, while carefully weighing the persistent GeneSight reimbursement headwinds and the company's ongoing efforts to demonstrate and communicate the economic value of its broader test portfolio to the market.